Clinical Trials Browser

Phase 2 × Alemtuzumab × Classical hematology × Clear all

Anemia, Aplastic, Hemoglobinuria, Paroxysmal, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms, Primary Myelofibrosis

NCT01049854 2018-08-21

CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant

Phase 2 Completed

20 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Bone Marrow Failure Disorders, Anemia, Sickle Cell, Immunologic Deficiency Syndromes, Leukemia, Lymphoma, Metabolism, Inborn Errors, Histiocytosis, beta-Thalassemia

NCT00301834 2017-09-28

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

Phase 2 Completed

35 enrolled 11 charts

Classical hematologyMyeloidOther hematologic neoplasm

Congenital amegakaryocytic thrombocytopenia, Neutropenia, Severe Congenital, Autosomal Recessive 3, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Chronic-Phase, Anemia, Diamond-Blackfan

NCT01191749 2017-05-09

Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)

Phase 2 Terminated

7 enrolled 6 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Aplastic, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Large Granular Lymphocytic

NCT00683046 2016-11-22

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

Phase 2 Completed

204 enrolled 7 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Aplastic, Blast Crisis, Hodgkin Disease, Leukemia, Lymphoid, Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT00533923 2016-07-18

Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

Phase 2 Completed

25 enrolled

Classical hematologyLymphoidMyeloidPlasma cell

Anemia, Aplastic, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis

NCT00578903 2016-04-22

Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia

Phase 2 Terminated

22 enrolled 11 charts

Classical hematologyLymphoid

Anemia, Aplastic, Lymphoma, Follicular

NCT00618969 2016-03-03

Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors

Phase 2 Completed

2 enrolled

Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Hemoglobinuria, Paroxysmal, Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT00895739 2013-08-12

Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure

Phase 2 Unknown

50 enrolled

Classical hematology

Anemia, Aplastic, Neoplasms

Clinical Trials

ALBUM

CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia

Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors

Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure